792 results match your criteria Tourette Syndrome and Other Tic Disorders


The Potential of Cannabinoid-Based Treatments in Tourette Syndrome.

CNS Drugs 2019 Apr 11. Epub 2019 Apr 11.

Department of Psychiatry, Yale University, Yale Child Study Center, New Haven, CT, USA.

Novel pharmacological treatments are needed for Tourette syndrome. Our goal was to examine the current evidence base and biological rationale for the use of cannabis-derived medications or medications that act on the cannabinoid system in Tourette syndrome. We conducted a comprehensive literature search of PubMed for randomized controlled trials or clinical trials of cannabis-derived medications in Tourette syndrome. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-019-00627-1
Publisher Site
http://dx.doi.org/10.1007/s40263-019-00627-1DOI Listing
April 2019
3 Reads

Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies.

Am J Psychiatry 2019 Mar;176(3):217-227

The Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston (Yu, Illmann, Osiecki, Smoller, Pauls, Neale, Scharf); the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Mass. (Yu, Neale, Scharf); the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles (Sul, Huang, Zelaya, Ophoff, Freimer, Coppola); the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Sul, Huang, Zelaya, Freimer, Coppola); the Department of Molecular Biology and Genetics, Democritus University of Thrace, Xanthi, Greece (Tsetsos); the Department of Biological Sciences, Purdue University, West Lafayette, Ind. (Tsetsos, Paschou); deCODE Genetics/Amgen, Reykjavik, Iceland (Nawaz, H. Stefansson, K. Stefansson); the Bioinformatics Interdepartmental Program, University of California, Los Angeles (Huang, Zelaya); the Department of Psychiatry, University of California, San Francisco (Darrow); the Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco (Hirschtritt, Willsey); the Department of Psychiatry, Massachusetts General Hospital, Boston (Greenberg, Roffman, Buckner); the Clinic of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany (Muller-Vahl); the Institute of Human Genetics, Hannover Medical School, Hannover, Germany (Stuhrmann); McGill University Health Center, University of Montreal, McGill University Health Centre, Montreal (Dion); the Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal (Rouleau); the Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna (Aschauer, Stamenkovic); Biopsychosocial Corporation, Vienna (Aschauer, Schlögelhofer); University Health Network, Youthdale Treatment Centres, and University of Toronto, Toronto (Sandor); the Krembil Research Institute, University Health Network, Hospital for Sick Children, and University of Toronto, Toronto (Barr); Johns Hopkins University School of Medicine, Baltimore (Grados, Singer); the Institute of Human Genetics, University Hospital Bonn, University of Bonn Medical School, Bonn, Germany (Nöthen); the Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (Hebebrand, Hinney); the Yale Child Study Center and the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (King, Fernandez); the Institute of Medical Chemistry, Molecular Biology, and Pathobiochemistry, Semmelweis University, Budapest, Hungary (Barta); Vadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary (Tarnok, Nagy); the Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany (Depienne); Sorbonne Universités, UPMC Université Paris 06, UMR S 1127, CNRS UMR 7225, ICM, Paris (Depienne, Worbe, Hartmann); French Reference Centre for Gilles de la Tourette Syndrome, Groupe Hospitalier Pitié-Salpêtrière, Paris (Worbe, Hartmann); Assistance Publique-Hôpitaux de Paris, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris (Worbe, Hartmann); Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York (Budman); Child Neuropsychiatry, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy (Rizzo); the Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Lyon); the Department of Psychiatry, University of Utah, Salt Lake City (McMahon); Children's Mercy Hospital, Kansas City, Mo. (Batterson); the Department of Psychiatry, University Medical Center Groningen and Rijksuniversity Groningen, and Drenthe Mental Health Center, Groningen, the Netherlands (Cath); the Department of Neurology, Fixel Center for Neurological Diseases, McKnight Brain Institute, University of Florida, Gainesville (Malaty, Okun); Pennsylvania State University College of Medicine, Hershey (Berlin); Marquette University and University of Wisconsin-Milwaukee, Milwaukee (Woods); Tripler Army Medical Center and University of Hawaii John A. Burns School of Medicine, Honolulu (Lee); Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston (Jankovic); the Division of Psychiatry, Department of Neuropsychiatry, University College London (Robertson); the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati (Gilbert); Children's Hospital of Philadelphia, Philadelphia (Brown); the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami (Coffey); the Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Dietrich, Hoekstra); University of Iowa Carver College of Medicine, Iowa City (Kuperman); the Department of Pediatrics, University of Washington, Seattle (Zinner); the Department of Pediatrics, Landspitalinn University Hospital, Reykjavik, Iceland (Luðvigsson, Thorarensen); the Faculty of Medicine, University of Iceland, Reykjavík, Iceland (Sæmundsen, Stefansson); the State Diagnostic and Counselling Centre, Kópavogur, Iceland (Sæmundsen); the Department of Genetics and the Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (Atzmon, Barzilai); the Department of Human Biology, Haifa University, Haifa, Israel (Atzmon); the Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany (Wagner); the Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany (Moessner); SUNY Downstate Medical Center Brooklyn, New York (C.M. Pato, M.T. Pato, Knowles); the Athinoula A. Martinos Center for Biomedical Research, Department of Radiology, Massachusetts General Hospital, Charlestown (Roffman, Buckner); the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Smoller); the Center for Brain Science and Department of Psychology, Harvard University, Cambridge, Mass. (Buckner); the Institute for Neurodegenerative Diseases, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco (Willsey); the Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers, the State University of New Jersey, Piscataway (Tischfield, Heiman); the Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, Amsterdam (Posthuma); the Division of Genetic Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tenn. (Cox, Davis); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston (Neale); the Department of Psychiatry, Genetics Institute, University of Florida, Gainesville (Mathews); and the Department of Neurology, Brigham and Women's Hospital, and the Department of Neurology, Massachusetts General Hospital, Boston (Scharf).

Objective:: Tourette's syndrome is polygenic and highly heritable. Genome-wide association study (GWAS) approaches are useful for interrogating the genetic architecture and determinants of Tourette's syndrome and other tic disorders. The authors conducted a GWAS meta-analysis and probed aggregated Tourette's syndrome polygenic risk to test whether Tourette's and related tic disorders have an underlying shared genetic etiology and whether Tourette's polygenic risk scores correlate with worst-ever tic severity and may represent a potential predictor of disease severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2018.18070857DOI Listing
March 2019
286 Reads
12.295 Impact Factor

Non-invasive Brain Stimulation for the Rehabilitation of Children and Adolescents With Neurodevelopmental Disorders: A Systematic Review.

Front Psychol 2019 6;10:135. Epub 2019 Feb 6.

Scientific Institute, IRCCS E. Medea, Pasian di Prato, Udine, Italy.

In the last years, there has been a growing interest in the application of different non-invasive brain stimulation techniques to induce neuroplasticity and to modulate cognition and behavior in adults. Very recently, different attempts have been made to induce functional plastic changes also in pediatric populations. Importantly, not only sensorimotor processing, but also higher-level functions have been addressed, with the aim to boost rehabilitation in different neurodevelopmental disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fpsyg.2019.00135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373438PMC
February 2019
3 Reads

The histidine decarboxylase model of tic pathophysiology: a new focus on the histamine H receptor.

Br J Pharmacol 2019 Feb 4. Epub 2019 Feb 4.

Department of Psychiatry, Yale University, New Haven, Connecticut, USA.

Histamine dysregulation was implicated as a rare cause of Tourette syndrome and other tic disorders a decade ago by a landmark genetic study in a high density family pedigree, which implicated a hypomorphic mutation in the histidine decarboxylase (Hdc) gene as a rare but high penetrance genetic cause. Studies in Hdc knockout (KO) mice have confirmed that this mutation causes tic-relevant behavioural and neurochemical abnormalities that parallel what is seen in patients and thus validate the KO as a potentially informative model of tic pathophysiology. Recent studies have focused on the potential role of the histamine H receptor in this model, and by association in tic disorders and related neuropsychiatric conditions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bph.14606
Publisher Site
http://dx.doi.org/10.1111/bph.14606DOI Listing
February 2019
10 Reads

Tic disorders revisited: introduction of the term "tic spectrum disorders".

Eur Child Adolesc Psychiatry 2019 Jan 19. Epub 2019 Jan 19.

Clinic of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany.

Although the DSM-5 chronic motor tic disorder (CMTD) and Tourette syndrome (TS) are distinct diagnostic categories, there is no genetic or phenotypic evidence that supports this diagnostic categorization. The aim of this study was to compare patients with both diagnoses along a number of clinical characteristics to provide further diagnostic clarity. Our sample consisted of 1018 patients (including adult and child patients) suffering from chronic tic disorders. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00787-018-01272-7
Publisher Site
http://dx.doi.org/10.1007/s00787-018-01272-7DOI Listing
January 2019
8 Reads

Merging the Pathophysiology and Pharmacotherapy of Tics.

Tremor Other Hyperkinet Mov (N Y) 2018 9;8:595. Epub 2019 Jan 9.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: Anatomically, cortical-basal ganglia-thalamo-cortical (CBGTC) circuits have an essential role in the expression of tics. At the biochemical level, the proper conveyance of messages through these circuits requires several functionally integrated neurotransmitter systems. In this manuscript, evidence supporting proposed pathophysiological abnormalities, both anatomical and chemical is reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D89C8F3CDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329776PMC
March 2019
3 Reads

Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders.

JAMA Neurol 2019 Jan 14. Epub 2019 Jan 14.

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Importance: There are limited data concerning the risk of metabolic and cardiovascular disorders among individuals with Tourette syndrome (TS) or chronic tic disorder (CTD).

Objective: To investigate the risk of metabolic and cardiovascular disorders among individuals with TS or CTD over a period of 40 years.

Design, Settings, And Participants: This longitudinal population-based cohort study included all individuals living in Sweden between January 1, 1973, and December 31, 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2018.4279DOI Listing
January 2019
11 Reads

Neuroimaging Applications in Tourette's Syndrome.

Int Rev Neurobiol 2018 12;143:65-108. Epub 2018 Oct 12.

Centre de Référence National Maladie Rare 'Syndrome Gilles de la Tourette, Paris, France; Sorbonne Université, UMR S 1127, CNRS UMR 7225, ICM, Paris, France; Départment de Physiologie, Hôpital Saint-Antoine, Paris, France.

Tics are neurodevelopmental hyperkinetic symptoms typically associated with unpleasant sensory experiences called premonitory urges. Tourette syndrome (TS) is the primary chronic tic disorder for which medical surveillance is most frequently required, and is associated with a complex phenotypical spectrum encompassing different types of abnormal behaviors. Animal models of tics support their link to phasic activity changes throughout the sensorimotor loop of the cortico-basal ganglia-thalamo-cortical network. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.irn.2018.09.008DOI Listing
October 2018
20 Reads

Tourette syndrome research highlights from 2017.

F1000Res 2018 23;7:1122. Epub 2018 Jul 23.

Psychiatry, Neurology, Radiology, and Neuroscience, Washington University School of Medicine, St. Louis, MO, 63110-1093, USA.

This is the fourth yearly article in the Tourette Syndrome Research Highlights series, summarizing research from 2017 relevant to Tourette syndrome and other tic disorders. The authors briefly summarize reports they consider most important or interesting. The  highlights from 2018 article is being drafted on the Authorea online authoring platform, and readers are encouraged to add references or give feedback on our selections using the comments feature on that page. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.15558.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107994PMC
July 2018
3 Reads

Differentiating tic-related from non-tic-related impairment in children with persistent tic disorders.

Compr Psychiatry 2018 11 25;87:38-45. Epub 2018 Aug 25.

Marquette University, 604 N. 16th St., Milwaukee, WI 53233, United States of America. Electronic address:

Children with persistent (chronic) tic disorders (PTDs) experience impairment across multiple domains of functioning, but given high rates of other non-tic-related conditions, it is often difficult to differentiate the extent to which such impairment is related to tics or to other problems. The current study used the Child Tourette's Syndrome Impairment Scale - Parent Report (CTIM-P) to examine parents' attributions of their child's impairment in home, school, and social domains in a sample of 58 children with PTD. Each domain was rated on the extent to which the parents perceived that impairment was related to tics versus non-tic-related concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.comppsych.2018.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240497PMC
November 2018
4 Reads

Psychopharmacotherapy of obsessive-compulsive symptoms within the framework of Tourette syndrome.

Curr Neuropharmacol 2018 Aug 27. Epub 2018 Aug 27.

Department of Child and Adolescent Psychiatry and Psychotherapy TU Dresden. Germany.

While Behavioral Therapy (BT) should be recommended as the first step in the treatment of OCD as well as TS, medication can be added for augmentation and in certain situations (e.g. family preference, BT not available or feasible) the priority may even reverse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1570159X16666180828095131DOI Listing
August 2018
15 Reads

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.

CNS Drugs 2018 Oct;32(10):917-938

Department of Psychiatry, University of British Columbia, Room A3-111, 938 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.

Background: Although antipsychotics are used to treat Tourette syndrome, there have been reports of paradoxical induction of tics by first- and second-generation antipsychotics.

Objective: The objective of this systematic review was to better characterize tics as the potential adverse effect of antipsychotics.

Methods: A literature search was performed, with no language restriction, using the MEDLINE, EMBASE, and PsycINFO databases for all publications up to January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-018-0559-8DOI Listing
October 2018
7 Reads
5.113 Impact Factor

Therapeutic Applications of Invasive Neuromodulation in Children and Adolescents.

Psychiatr Clin North Am 2018 09 17;41(3):479-483. Epub 2018 Jul 17.

Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address:

Although the application of noninvasive brain stimulation methods to children and adolescents has been frequently studied in depression, autism spectrum disorder, attention-deficit/hyperactivity disorder, and other neuropsychiatric disorders, invasive methods such as deep brain stimulation (DBS) and vagal nerve stimulation (VNS) have received less attention. DBS and VNS have demonstrated utility in young patients especially for dystonia and epilepsy. VNS has FDA clearance for intractable epilepsy in patients aged 4 years and older. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psc.2018.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092040PMC
September 2018

Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies.

Transl Psychiatry 2018 08 2;8(1):143. Epub 2018 Aug 2.

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Despite intense research, the underlying mechanisms and the etiology of Tourette's syndrome (TS) remain unknown. Data from molecular imaging studies targeting the dopamine system in Tourette patients are inconclusive. For a better understanding of the striatal dopamine function in adult dopamine-antagonist-free patients we performed a systematic review in August 2017 identifying 49 PET and SPECT studies on the topic of TS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41398-018-0202-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072751PMC
August 2018
6 Reads

Phenomenology and Clinical Correlates of Stimulus-Bound Tics in Gilles de la Tourette Syndrome.

Front Neurol 2018 22;9:477. Epub 2018 Jun 22.

Department of Neurology, Medical University of Warsaw, Warsaw, Poland.

Stimulus-bound tics (SBTs) belong to stimulus-induced behaviors and are defined as tics that occur in response to internal or external stimuli. The aim of the study was to assess the prevalence and associations of SBTs with other stimulus-triggered behaviors, premonitory urges and stimulus sensitization in Gilles de la Tourette syndrome (GTS). We performed a prospective, one-registration study in a cohort of 140 consecutive patients with GTS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.00477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024546PMC
June 2018
4 Reads

Transcranial Magnetic Stimulation in Tourette Syndrome: A Historical Perspective, Its Current Use and the Influence of Comorbidities in Treatment Response.

Brain Sci 2018 Jul 6;8(7). Epub 2018 Jul 6.

School of Medicine, Universidad de los Andes, Bogotá 111711, Colombia.

Background: Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder consisting of impairing motor and vocal tics which often persists adolescent and adult years. In this older refractory group, standard treatments such as pharmacotherapy and psychotherapeutic interventions may only have limited effects. Based on electrical cortical dysregulation in individuals with TS, a novel approach has employed brain stimulation strategies to modulate the putative aberrant neural electrical activity in pathways that may underlie tics, such as insula-supplementary motor area (SMA) connectivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/brainsci8070129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071080PMC
July 2018
20 Reads

European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents.

Eur Child Adolesc Psychiatry 2019 Jan 7;28(1):91-109. Epub 2018 Jul 7.

Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

Genetic predisposition, autoimmunity and environmental factors [e.g. pre- and perinatal difficulties, Group A Streptococcal (GAS) and other infections, stress-inducing events] might interact to create a neurobiological vulnerability to the development of tics and associated behaviours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00787-018-1190-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349795PMC
January 2019
13 Reads

Combined habit reversal training and exposure response prevention in a group setting compared to individual training: a randomized controlled clinical trial.

Eur Child Adolesc Psychiatry 2019 Jan 28;28(1):57-68. Epub 2018 Jun 28.

Center for Child and Adolescent Psychiatry, Aarhus University Hospital Risskov, Risskov, Denmark.

Chronic tic disorders may have a huge influence on quality of life. Habit reversal training (HRT) and exposure response prevention (ERP) are effective treatments. In a blinded assessed, open trial, this study evaluates the effectiveness of a newly developed Scandinavian tic treating manual designed to treat adolescents with a chronic tic disorder, combining HRT and ERP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00787-018-1187-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349803PMC
January 2019
19 Reads

Efficacy of repetitive transcranial magnetic stimulation for Tourette syndrome: A systematic review and meta-analysis.

Brain Stimul 2018 Sep - Oct;11(5):1110-1118. Epub 2018 Jun 5.

Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Electronic address:

Background: While previous studies have investigated the effect of repetitive transcranial magnetic stimulation (rTMS) in treating Tourette syndrome (TS), the results remain inconclusive.

Objective: We aim to systematically review the existing literature related to the efficacy of rTMS in TS and synthesize the results through meta-analysis.

Methods: We searched for PubMed, Embase, Cochrane Library, and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2018.06.002DOI Listing
March 2019
7 Reads

DBS in pediatric patients: institutional experience.

Childs Nerv Syst 2018 Sep 24;34(9):1771-1776. Epub 2018 May 24.

Department of Neurosurgery, Florence Nightingale Hospital, Istanbul Bilim University, Abide-i Hurriyet Cad. No:164 Sisli, Istanbul, Turkey.

Introduction: DBS is initially used for treatment of essential tremor and Parkinson's disease in adults. In 1996, a child with severe life-threatening dystonia was offered DBS to the internal globus pallidus (GPi) with lasting efficacy at 20 years. Since that time, increasing number of children benefited from DBS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00381-018-3839-1DOI Listing
September 2018
15 Reads

Disentangling Tourette syndrome heterogeneity through hierarchical ascendant clustering.

Dev Med Child Neurol 2018 09 10;60(9):942-950. Epub 2018 May 10.

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, APHP, Paris, France.

Aim: To explore the heterogeneity of Tourette syndrome as part of a neurodevelopmental spectrum.

Method: Using hierarchical ascendant clustering based on tic symptoms, developmental milestones, and neurodevelopmental comorbidities, we analyzed the heterogeneity of Tourette syndrome phenotypes in a sample of 174 children and adolescents with Tourette syndrome referred to a tertiary university clinic.

Results: The model yielded three distinct clusters characterized as follows. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dmcn.13913DOI Listing
September 2018
4 Reads

Psychopharmacotherapy of Attention Deficit-Hyperactivity Disorder in Children with Comorbid Conditions.

Authors:
Ahmed Naguy

Pediatr Neurol 2018 05 27;82:7-12. Epub 2017 Sep 27.

Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, Kuwait. Electronic address:

One or more comorbidities occur in up to 80% of children with attention deficit-hyperactivity disorder. Attention deficit-hyperactivity disorder is also over-represented in several special populations. Pharmacotherapy can be challenging in these individuals with other conditions due to a suboptimal therapeutic response and an increased likelihood of adverse reactions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08878994173060
Publisher Site
http://dx.doi.org/10.1016/j.pediatrneurol.2017.09.010DOI Listing
May 2018
38 Reads
1.504 Impact Factor

Tourette's syndrome and its borderland.

Authors:
Jeremy S Stern

Pract Neurol 2018 Aug 10;18(4):262-270. Epub 2018 Apr 10.

The Gilles de la Tourette syndrome (or Tourette's syndrome) has a prevalence of 1% of children with a wide range of severity and associated comorbidities. The last 20 years have seen advances in the understanding of the syndrome's complex genetics and underlying neurobiology. Investigation with imaging and neurophysiology techniques indicate it is a neurodevelopmental condition with dysfunction of basal ganglia-cortical interactions, which are now also being studied in animal models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2017-001755DOI Listing
August 2018
2 Reads

Voluntary inhibitory motor control over involuntary tic movements.

Mov Disord 2018 07 6;33(6):937-946. Epub 2018 Mar 6.

Institute of Cognitive Neuroscience, University College London, London, UK.

Inhibitory control is crucial for normal adaptive motor behavior. In hyperkinesias, such as tics, disinhibition within the cortico-striato-thalamo-cortical loops is thought to underlie the presence of involuntary movements. Paradoxically, tics are also subject to voluntary inhibitory control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27346DOI Listing
July 2018
42 Reads

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Drugs 2018 04;78(5):525-541

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030, USA.

Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs). Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem. Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0874-xDOI Listing
April 2018
19 Reads

The nosology of tardive syndromes.

J Neurol Sci 2018 06 6;389:10-16. Epub 2018 Feb 6.

Parkinson's Disease and Movement Disorders Center, Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33613, United States.

Since the original description of side effects of neuroleptics, different terminologies and definitions for tardive dyskinesia (TD) and tardive syndrome (TS) have been used by different authors, and often these two terms have been used interchangeably. This paper proposes a nosology designed to define and clarify various terms and phenomenologies within the TS spectrum. We propose to use the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements, as well as to the analogous repetitive movements that can appear in the limbs, trunk, or pelvis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.008DOI Listing
June 2018
37 Reads

Clinical Utility of Screening for Anxiety and Depression in Children with Tourette Syndrome.

J Can Acad Child Adolesc Psychiatry 2018 Jan 1;27(1):15-21. Epub 2018 Jan 1.

Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta.

Background: Tourette syndrome (TS) is often co-morbid with attention deficit hyperactivity disorder (ADHD) and obsessive compulsive disorder (OCD). Studies of TS, anxiety and depression have found variable results depending on study methodology and sample characteristics. Our aim was to examine the clinical utility of routine screening for anxiety and depression in children with TS. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777687PMC
January 2018
4 Reads

Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome.

CNS Drugs 2018 01;32(1):33-45

Division of Neurology, Movement Disorders Clinic, Tourette Syndrome Center of Excellence, Children's Mercy Hospital, Professional Office Building, Office 1M02.35, 2240 Kenwood Avenue, Kansas City, MO, 64108, USA.

Tourette syndrome (TS) is a neurodevelopmental disorder of unknown etiology characterized by spontaneous, involuntary movements and vocalizations called tics. Once thought to be rare, TS affects 0.3-1% of the population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-017-0486-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843687PMC
January 2018
20 Reads

Thalamic Deep Brain Stimulation.

Prog Neurol Surg 2018 12;33:198-206. Epub 2018 Jan 12.

The use of deep brain stimulation (DBS) of the thalamus has been proven to be a safe and efficacious treatment for the management of many diseases. The most common indication for thalamic DBS remains essential tremor (ET), one of the most common movement disorders in the world. ET patients should be considered for surgical intervention when their tremor has demonstrated to be refractory to medication, a characteristic estimated to be present in roughly 50% of ET cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000481104DOI Listing
August 2018
1 Read

GABA and glutamate in children with Tourette syndrome: A H MR spectroscopy study at 7T.

Psychiatry Res Neuroimaging 2018 03 3;273:46-53. Epub 2018 Jan 3.

Department of Neurology, The Johns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD 21287, USA.

Tourette syndrome (TS) is characterized by presence of chronic, fluctuating motor and phonic tics. The underlying neurobiological basis for these movements is hypothesized to involve cortical-striatal-thalamo-cortical (CSTC) pathways. Two major neurotransmitters within these circuits are γ-aminobutyric acid (GABA) and glutamate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pscychresns.2017.12.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815927PMC
March 2018
45 Reads

Tourette disorder and other tic disorders.

Handb Clin Neurol 2018 ;147:343-354

Child Study Center, Yale School of Medicine, New Haven, CT, United States; Department of Psychiatry, Yale University, New Haven, CT, United States. Electronic address:

Tourette disorder is a developmental neuropsychiatric condition characterized by vocal and motor tics that can range in severity from mild to disabling. It represents one end of a spectrum of tic disorders and is estimated to affect 0.5-0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-63233-3.00023-3DOI Listing
July 2018
2 Reads

Botulinum toxin for motor and phonic tics in Tourette's syndrome.

Cochrane Database Syst Rev 2018 Jan 5;1:CD012285. Epub 2018 Jan 5.

Department of Neurology, G.B. Pant Hospital, New Delhi, India, 110002.

Background: Gilles de la Tourette syndrome, or Tourette's syndrome, is defined as the presence of both motor and vocal (phonic) tics for more than 12 months, that manifest before the age of 18 years, in the absence of secondary causes. Treatment of motor and phonic tics is difficult and challenging.

Objectives: To determine the safety and effectiveness of botulinum toxin in treating motor and phonic tics in people with Tourette's syndrome, and to analyse the effect of botulinum toxin on premonitory urge and sensory tics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012285.pub2DOI Listing
January 2018
33 Reads

[Tourette Syndrome: Clinical Features and Pathophysiology].

Authors:
Yoshiko Nomura

Brain Nerve 2017 Dec;69(12):1373-1385

Yoshiko Nomura Neurological Clinic for Children.

Tourette syndrome (TS) is a neuropsychiatric disorder with the onset in childhood. TS is a form of tic disorders, and characterized by the motor and vocal tics, and comorbidities such as attention deficit hyperkinetic and obsessive compulsive disorders. These symptoms appear age dependently, showing a wax and wane course, and subside or abolish by the late teens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416200922DOI Listing
December 2017
28 Reads

Paroxysmal Kinesigenic Dyskinesia.

Tremor Other Hyperkinet Mov (N Y) 2017 12;7:529. Epub 2017 Dec 12.

Department of Neurology, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Background: Paroxysmal kinesigenic dyskinesia (PKD) is a rare condition associated with heterozygous mutations in the proline-rich transmembrane protein 2 () gene.

Phenomenology Shown: In this article we illustrate the phenomenology of PKD in a male previously misdiagnosed with Tourette's syndrome.

Educational Value: Regardless of the underlying phenotype, PKD is highly responsive to some antiepileptic drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D8R79N2FDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740227PMC
September 2018
10 Reads

Tourette syndrome and other chronic tic disorders: an update on clinical management.

Expert Rev Neurother 2018 02 8;18(2):125-137. Epub 2017 Dec 8.

a Department of Clinical Neurosciences , Cumming School of Medicine, University of Calgary and Hotchkiss Brain Institute , Calgary , Canada.

Introduction: The management of Tourette syndrome (TS) and other chronic tic disorders occurs in multiple stages and begins with comprehensive assessment and complex psychoeducation. Behavioral and pharmacological interventions (second stage) are needed when tics cause physical or psychosocial impairment. Deep brain stimulation surgery or experimental therapies represent the third stage. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737175.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737175.2018.1413938DOI Listing
February 2018
9 Reads

Tourette syndrome research highlights from 2016.

Authors:
Kevin J Black

F1000Res 2017 11;6:1430. Epub 2017 Aug 11.

Departments of Psychiatry, Neurology, Radiology, and Neuroscience, Washington University School of Medicine, St. Louis, MO, 63110, USA.

This article presents highlights chosen from research that appeared during 2016 on Tourette syndrome and other tic disorders. Selected articles felt to represent meaningful advances in the field are briefly summarized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.12330.2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621096PMC
August 2017
2 Reads

Social cognition and self-other distinctions in neuropsychiatry: Insights from schizophrenia and Tourette syndrome.

Authors:
Clare M Eddy

Prog Neuropsychopharmacol Biol Psychiatry 2018 03 28;82:69-85. Epub 2017 Nov 28.

BSMHFT National Centre for Mental Health, Birmingham, and College of Medical and Dental Sciences, University of Birmingham, UK. Electronic address:

Impairments in social cognition may reflect dysfunction of disorder specific or disorder general mechanisms. Although cross-disorder comparison may prove insightful, few studies have compared social cognition in different neuropsychiatric disorders. Parallel investigation of schizophrenia and Tourette syndrome (TS) is encouraged by similarities including the presence of problematic social behavior, echophenomena, emotional dysregulation and dopamine dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pnpbp.2017.11.026DOI Listing
March 2018
3 Reads

Tourette Syndrome and Chronic Tic Disorders: The Clinical Spectrum Beyond Tics.

Int Rev Neurobiol 2017 9;134:1461-1490. Epub 2017 Jun 9.

University of Calgary, Calgary, AB, Canada.

The clinical surveillance and active management of Tourette syndrome (TS) and other primary chronic tic disorders cannot be limited to tics, as these patients manifest a spectrum of sensory-, behavioral-, cognitive-, and sleep-related problems that have a major impact on their functioning and quality of life, influencing enormously clinical decision making on a routine basis. The sensory phenomena of primary tic disorders consist of premonitory urges and heightened sensitivity to external somatosensory and interoceptive stimuli. Recent evidence suggests that raised interoceptive awareness may be related to the classical premonitory urges associated with tics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.irn.2017.05.006DOI Listing
April 2018
13 Reads

Imitation inhibition in children with Tourette syndrome.

J Neuropsychol 2019 Mar 12;13(1):82-95. Epub 2017 Aug 12.

Department of Paediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, Germany.

Objective: Echopraxia, that is, the open and automatic imitation of other peoples' actions, is common in patients with Gilles de la Tourette syndrome, autism spectrum disorder, and also those with frontal lobe lesions. While systematic reaction time tasks have confirmed increased automatic imitation in the latter two groups, adult patients with Tourette syndrome appear to compensate for automatic imitation tendencies by an overall slowing in response times. However, whether children with Tourette syndrome are already able to inhibit automatic imitation tendencies has not been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnp.12132DOI Listing
March 2019
23 Reads

Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome.

Sci Rep 2017 07 24;7(1):6292. Epub 2017 Jul 24.

Laboratoire de Neurosciences Cognitives, Institut National de la Santé et de la Recherche Médicale, Paris, France.

The dopamine partial agonist aripiprazole is increasingly used to treat pathologies for which other antipsychotics are indicated because it displays fewer side effects, such as sedation and depression-like symptoms, than other dopamine receptor antagonists. Previously, we showed that aripiprazole may protect motivational function by preserving reinforcement-related signals used to sustain reward-maximization. However, the effect of aripiprazole on more cognitive facets of human reinforcement learning, such as learning from the forgone outcomes of alternative courses of action (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-06547-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524760PMC
July 2017
40 Reads

[Gilles de la Tourette Syndrome: Symptoms, Causes and Therapy].

Psychother Psychosom Med Psychol 2017 Jun 22;67(6):252-268. Epub 2017 Jun 22.

Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover.

Gilles de la Tourette syndrome is a chronic neuropsychiatric movement disease with combined motor tics and at least one vocal tic for a minimum period of 1 year. It typically begins in the childhood (under 18 years of age).Most of the patients with Tourette syndrome have comorbidities, which often impair their quality of life more than the tics themselves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0043-103269DOI Listing
June 2017
16 Reads

Procedural learning in Tourette syndrome, ADHD, and comorbid Tourette-ADHD: Evidence from a probabilistic sequence learning task.

Brain Cogn 2017 10 12;117:33-40. Epub 2017 Jul 12.

Department of Neuroscience, Georgetown University, Box 571464, Washington, DC 20057-1464, United States. Electronic address:

Procedural memory, which is rooted in the basal ganglia, plays an important role in the implicit learning of motor and cognitive skills. Few studies have examined procedural learning in either Tourette syndrome (TS) or Attention Deficit Hyperactivity Disorder (ADHD), despite basal ganglia abnormalities in both of these neurodevelopmental disorders. We aimed to assess procedural learning in children with TS (n=13), ADHD (n=22), and comorbid TS-ADHD (n=20), as well as in typically developing children (n=21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bandc.2017.06.009DOI Listing
October 2017
33 Reads

Creativity Assessment in Subjects with Tourette Syndrome vs. Patients with Parkinson's Disease: A Preliminary Study.

Brain Sci 2017 Jul 9;7(7). Epub 2017 Jul 9.

Tourette Syndrome Centre, Clinical and Research Galeazzi Hospital, Milan 20161, Italy.

(1) Background: Literature suggests that high levels of dopamine are associated with creative thoughts. Tourette Syndrome (TS) patients have high dopamine levels, while Parkinson's Disease (PD) subjects have low dopamine levels. Consequently, TS individuals are supposed to have a major and PD patients less creative output. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/brainsci7070080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532593PMC
July 2017
2 Reads

Autism Spectrum Symptoms in a Tourette's Disorder Sample.

J Am Acad Child Adolesc Psychiatry 2017 Jul 11;56(7):610-617.e1. Epub 2017 May 11.

University of Florida, Gainesville. Electronic address:

Objective: Tourette's disorder (TD) and autism spectrum disorder (ASD) share clinical features and possibly an overlapping etiology. The aims of this study were to examine ASD symptom rates in participants with TD, and to characterize the relationships between ASD symptom patterns and TD, obsessive-compulsive disorder (OCD), and attention-deficit/hyperactivity disorder (ADHD).

Method: Participants with TD (n = 535) and their family members (n =234) recruited for genetic studies reported TD, OCD, and ADHD symptoms and completed the Social Responsiveness Scale Second Edition (SRS), which was used to characterize ASD symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaac.2017.05.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648014PMC
July 2017
23 Reads

Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial.

Lancet Neurol 2017 08 20;16(8):610-619. Epub 2017 Jun 20.

Unité Mixte de Recherche (UMR) S1127, Centre National de la Recherche Scientifique (CNRS), UMR 7225, Institut du Cerveau et de la Moelle Epinière, Paris, France; AP-HP, Personalised Neurology and Psychiatry University Department, Hôpitaux Universitaires Henri Mondor - Albert Chenevier, Université Paris Est Créteil, Créteil, France; Department of Mental Health and Psychiatry, Geneva University Hospital, University of Geneva, Geneva, Switzerland.

Background: Deep brain stimulation (DBS) has been proposed to treat patients with severe Tourette's syndrome, and open-label trials and two small double-blind trials have tested DBS of the posterior and the anterior internal globus pallidus (aGPi). We aimed to specifically assess the efficacy of aGPi DBS for severe Tourette's syndrome.

Methods: In this randomised, double-blind, controlled trial, we recruited patients aged 18-60 years with severe and medically refractory Tourette's syndrome from eight hospitals specialised in movement disorders in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(17)30160-6DOI Listing
August 2017
56 Reads

Valbenazine: First Global Approval.

Authors:
Esther S Kim

Drugs 2017 Jul;77(10):1123-1129

Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.

Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-017-0770-9DOI Listing
July 2017
9 Reads

How Much Do We Know about Adult-onset Primary Tics? Prevalence, Epidemiology, and Clinical Features.

Authors:
Daphne Robakis

Tremor Other Hyperkinet Mov (N Y) 2017 17;7:441. Epub 2017 May 17.

Department of Neurology, Yale School of Medicine, Yale University, New Haven, CT, USA.

Background: Tic disorders are generally considered to be of pediatric onset; however, reports of adult-onset tics exist in the literature. Tics can be categorized as either primary or secondary, with the latter being the larger group in adults. Primary or idiopathic tics that arise in adulthood make up a subset of tic disorders whose epidemiologic and clinical features have not been well delineated. Read More

View Article

Download full-text PDF

Source
http://www.tremorjournal.org/index.php/tremor/article/view/4
Publisher Site
http://dx.doi.org/10.7916/D8SQ95NDDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440657PMC
May 2017
10 Reads

Abnormal Brain Connectivity Spectrum Disorders Following Thimerosal Administration: A Prospective Longitudinal Case-Control Assessment of Medical Records in the Vaccine Safety Datalink.

Dose Response 2017 Jan-Mar;15(1):1559325817690849. Epub 2017 Mar 16.

Department of Research, The Institute of Chronic Illnesses, Inc, Silver Spring, MD, USA.

Background: Autism spectrum disorder (ASD), tic disorder (TD), and hyperkinetic syndrome of childhood (attention deficit disorder [ADD]/attention deficit hyperactivity disorder [ADHD]) are disorders recently defined as abnormal connectivity spectrum disorders (ACSDs) because they show a similar pattern of abnormal brain connectivity. This study examines whether these disorders are associated with exposure to thimerosal, a mercury (Hg)-based preservative.

Methods: A hypothesis testing case-control study evaluated the Vaccine Safety Datalink for the potential dose-dependent odds ratios (ORs) for diagnoses of ASD, TD, and ADD/ADHD compared to controls, following exposure to Hg from thimerosal-containing type b vaccines administrated within the first 15 months of life. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1559325817690849
Publisher Site
http://dx.doi.org/10.1177/1559325817690849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433557PMC
March 2017
33 Reads

Altered expression of histamine signaling genes in autism spectrum disorder.

Transl Psychiatry 2017 05 9;7(5):e1126. Epub 2017 May 9.

Lieber Institute for Brain Development, Clinical Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.

The histaminergic system (HS) has a critical role in cognition, sleep and other behaviors. Although not well studied in autism spectrum disorder (ASD), the HS is implicated in many neurological disorders, some of which share comorbidity with ASD, including Tourette syndrome (TS). Preliminary studies suggest that antagonism of histamine receptors 1-3 reduces symptoms and specific behaviors in ASD patients and relevant animal models. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/tp.2017.87
Publisher Site
http://dx.doi.org/10.1038/tp.2017.87DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534955PMC
May 2017
35 Reads